Former B+L leader to return to the helm 

Former B+L leader to return to the helm 

Bausch + Lomb Corp. has named Brent Saunders CEO and chair of the Board of Directors, effective March 6. Saunders previously served as CEO from 2010 to 2013.  

Concurrent with the appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director.  

Additionally, effective upon Saunders’ appointment as chair of the board, Thomas W. Ross, Sr. will become the lead independent director of the board. 

To facilitate an orderly transition, Saunders will join Bausch + Lomb on Feb. 16, in an advisory capacity, where he will work closely with Papa. 

“I am honored to once again lead Bausch + Lomb during this exciting time as a new publicly traded company,” Saunders said in a release. “I am confident in our future, and I look forward to once again working alongside the more than 12,000 employees who live by and aspire to achieve the Bausch + Lomb mission of helping people see better to live better.” 

Bausch + Lomb is one of the Rochester area’s largest manufacturers with roughly 1,200 local employees. 

Saunders brings more than 25 years of leadership in health care, having served in president, CEO and chairman roles, among others, at several global pharmaceutical and health care companies, including Schering-Plough Corp., Forest Laboratories Inc., Actavis plc, Allergan plc and The Beauty Health Company. 

“We are delighted that the board’s thorough search process has concluded with the appointment of Brent Saunders as Bausch + Lomb’s next CEO,” said Ross in a statement, who also praised Papa’s contributions to the company. “(Saunders’) strong inner-working knowledge of the company and unparalleled executive leadership experience in health care make him the ideal person to lead Bausch + Lomb at this pivotal time in our 170-year history.

He added, “We are confident that Bausch + Lomb is well-positioned for the future under Brent’s leadership as the company continues to focus on completing its full separation from Bausch Health.”  

[email protected] / (585) 653-4021 

l